Source-grounded facts extracted from Merck & Co., Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding a report on political contributions at the 2026-05-26 meeting.
“6. Shareholder proposal regarding a report on political contributions: 227,074,175 votes FOR 1,606,594,343 votes AGAINST 23,851,882 shares abstained from voting 283,983,197 broker non votes”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding a report on healthcare coverage gaps at the 2026-05-26 meeting.
“5. Shareholder proposal regarding a report on healthcare coverage gaps: 23,597,628 votes FOR 1,811,874,302 votes AGAINST 22,048,470 shares abstained from voting 283,983,197 broker non votes”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding a report on DEI risks in federal contracting at the 2026-05-26 meeting.
“4. Shareholder proposal regarding a report on DEI risks in federal contracting: 22,754,046 votes FOR 1,812,455,404 votes AGAINST 22,310,950 shares abstained from voting 283,983,197 broker non votes”
Merck & Co., Inc. shareholders approved Ratification of the appointment of the Company’s independent registered public accounting firm for 2026 at the 2026-05-26 meeting.
“3. Ratification of the appointment of the Company’s independent registered public accounting firm for 2026: 2,011,579,504 votes FOR 126,487,980 votes AGAINST 3,436,113 shares abstained from voting”
Merck & Co., Inc. shareholders approved Non-binding advisory vote to approve the compensation of our named executive officers at the 2026-05-26 meeting.
“2. Non-binding advisory vote to approve the compensation of our named executive officers: 1,730,192,132 votes FOR 109,310,633 votes AGAINST 18,017,635 shares abstained from voting 283,983,197 broker non votes”
Merck & Co., Inc. shareholders approved Election of Directors at the 2026-05-26 meeting.
“1. The following nominees were elected to the Company’s Board of Directors to hold office until the Company’s next Annual Meeting of Shareholders and received the number of votes set forth opposite their names: Names Votes For Votes Against Abstentions Broker Non-Votes Douglas M. Baker, Jr. 1,849,536,622 5,420,062 2,563,716 283,983,197 Mary Ellen Coe 1,839,523,954 15,699,812 2,296,634 283,983,197 Pamela J. Craig 1,805,030,600 48,837,633 3,652,167 283,983,197 Robert M. Davis 1,729,744,541 117,936,777 9,839,082 283,983,197 Thomas H. Glocer 1,733,084,321 121,844,310 2,591,769 283,983,197 Surendralal L. Karsanbhai 1,832,639,394 21,031,536 3,849,470 283,983,197 Risa J. Lavizzo-Mourey, M.D. 1,838,747,154 16,432,343 2,340,903 283,983,197 Stephen L. Mayo, Ph.D. 1,849,015,649 6,015,256 2,489,495 283,983,197 Paul B. Rothman, M.D. 1,835,774,436 19,226,470 2,519,494 283,983,197 Patricia F. Russo 1,636,745,520 217,186,188 3,588,692 283,983,197 Christine E. Seidman, M.D. 1,848,205,743 7,001,420 2,31”
Merck & Co., Inc. reported first quarter of 2026 results: revenue $16,286, net income (4,240), EPS (1.72). Guidance raised.
“First Quarter $ in millions, except EPS amounts 2026 2025 Change Change Ex- Exchange Sales $ 16,286 $ 15,529 5 % 3 % GAAP net (loss) income 2 (4,240 ) 5,079 N/M N/M Non-GAAP net (loss) income that excludes certain items 2,3* (3,156 ) 5,611 N/M N/M GAAP EPS (1.72 ) 2.01 N/M N/M”
Merck & Co., Inc. announced a restructuring with charges of approximately $3.0 billion affecting sales and administrative organizations, research and development, global real estate footprint, manufacturing network.
“expected to be substantially completed by the end of 2029. The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash, relating primarily to employee separation expense and contractual termination costs. The remainder of the costs will be non-cash,”
Merck & Co., Inc.: Amended and restated by-laws to revise and update indemnification provisions, with other non-substantive and conforming revisions (effective 2024-11-19).
“On November 19, 2024, the Board approved and adopted amended and restated by-laws of the Company (as so amended and restated, the "By-Laws"), effective as of such date. The amendments to the By-Laws revise and update the indemnification provisions applicable to the Company's directors, officers, employees and agents.”
Surendralal L. “Lal” Karsanbhai was elected as Director at Merck & Co., Inc..
“announcing the election of Surendralal L. “Lal” Karsanbhai to the Company’s Board of Directors (the “Board”), effective January 1, 2025.”
Merck & Co., Inc. reported first quarter of 2024 results: revenue $15,775, net income 4,762, EPS GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07. Guidance raised.
“Financial Summary First Quarter $ in millions, except EPS amounts 2024 2023 Change Change Ex- Exchange Sales $ 15,775 $ 14,487 9 % 12 % GAAP net income 1 4,762 2,821 69 % 76 % Non-GAAP net income that excludes certain items 1,2* 5,279 3,564 48 % 54 % GAAP EPS 1.87 1.11 68 % 76 % Non-GAAP EPS that excludes certain items 2* 2.07 1.40 48 % 54 %”
Peter C. Wendell departed as Director at Merck & Co., Inc..
“On February 15, 2024, Peter C. Wendell gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2024 Annual Meeting of Shareholders on May 28, 2024.”
Merck & Co., Inc. reported fourth quarter and full year of 2023 results: revenue $14.6 billion.
“Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022”
Merck & Co., Inc. announced a restructuring with charges of approximately $4.0 billion affecting the Company's Human Health global manufacturing network … and also optimize the Animal Health global manufacturing network.
“expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the $4.0 billion will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested; the remainder of the costs”
Dalton E. Smart III was appointed as Senior Vice President Finance – Global Controller and principal accounting officer at Merck & Co., Inc..
“On November 28, 2023, the Board of Directors (the “Board”) of the Company elected Dalton E. Smart III to serve as Senior Vice President Finance – Global Controller of the Company, effective December 4, 2023, making him the Company’s principal accounting officer.”
Rita Karachun resigned as Senior Vice President Finance – Global Controller and principal accounting officer at Merck & Co., Inc..
“On November 21, 2023, Rita Karachun, Senior Vice President Finance – Global Controller and principal accounting officer of Merck & Co., Inc. (the “Company”), gave notice of her intention to resign from this position effective December 4, 2023.”
Merck & Co., Inc. updated its the third quarter of 2023 guidance (raised).
“Incorporated by reference is a press release issued by Merck & Co., Inc. on October 26, 2023, regarding earnings for the third quarter of 2023, attached as Exhibit 99.1.”
Merck & Co., Inc. reported the second quarter of 2023 results: revenue $15.0 Billion, net income $(5,975) million, EPS ($2.35) per share. Guidance raised.
“Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% ○ GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 53% ○ LAGEVRIO Sales Declined 83% to $203 Million; Excluding the Impact of Foreign Exchange, Sales Declined 82% - GAAP Loss per Share Was $2.35; Non-GAAP Loss per Share Was $2.06; GAAP and Non-GAAP Loss per Share Include a Charge of $4.02 per Share for the Acquisition of Prometheus - Presented Compelling Data in Earlier Stages of Cancer at 2023 ASCO Annual Meeting, Including: o Positive Phase 3 Results From KEYNOTE-671 Trial o Promising New Data From Phase 2”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding an independent board chairman at the 2023-05-23 meeting.
“10. Shareholder proposal regarding an independent board chairman: 604,053,803 votes FOR 1,258,675,075 votes AGAINST or an affirmative vote of 32.42% of the total votes cast. 7,108,982 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding a congruency report of partnerships with globalist organizations at the 2023-05-23 meeting.
“9. Shareholder proposal regarding a congruency report of partnerships with globalist organizations: 21,684,751 votes FOR 1,822,435,800 votes AGAINST or an affirmative vote of 1.17% of the total votes cast. 25,717,309 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding patents and access at the 2023-05-23 meeting.
“8. Shareholder proposal regarding patents and access: 571,866,383 votes FOR 1,266,959,770 votes AGAINST or an affirmative vote of 31.09% of the total votes cast. 31,011,707 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding indirect political spending at the 2023-05-23 meeting.
“7. Shareholder proposal regarding indirect political spending: 134,569,780 votes FOR 1,706,198,205 votes AGAINST or an affirmative vote of 7.31% of the total votes cast. 29,069,875 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding access to COVID-19 products at the 2023-05-23 meeting.
“6. Shareholder proposal regarding access to COVID-19 products: 574,496,614 votes FOR 1,264,355,494 votes AGAINST or an affirmative vote of 31.24% of the total votes cast. 30,985,752 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders rejected Shareholder proposal regarding business operations in China at the 2023-05-23 meeting.
“5. Shareholder proposal regarding business operations in China: 69,754,041 votes FOR 1,748,779,515 votes AGAINST or an affirmative vote of 3.83% of the total votes cast. 51,304,304 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders approved Ratification of the appointment of the Company’s independent registered public accounting firm for 2023 at the 2023-05-23 meeting.
“4. Ratification of the appointment of the Company’s independent registered public accounting firm for 2023: 2,043,709,187 votes FOR 124,208,470 votes AGAINST or an affirmative vote of 94.27% of the total votes cast. 5,395,666 shares abstained from voting.”
Merck & Co., Inc. shareholders approved Non-binding advisory vote to approve the frequency of future votes to approve the compensation of our named executive officers at the 2023-05-23 meeting.
“3. Non-binding advisory vote to approve the frequency of future votes to approve the compensation of our named executive officers: 1,835,407,619 votes ONE YEAR 3,907,809 votes TWO YEARS 24,899,809 votes THREE YEARS or an affirmative vote of 99.98% of the total votes cast. 5,622,623 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders approved Non-binding advisory vote to approve the compensation of our named executive officers at the 2023-05-23 meeting.
“2. Non-binding advisory vote to approve the compensation of our named executive officers: 1,697,425,819 votes FOR 161,718,633 votes AGAINST or an affirmative vote of 91.30% of the total votes cast. 10,693,408 shares abstained from voting. 303,475,463 broker non votes.”
Merck & Co., Inc. shareholders approved Election of Directors at the 2023-05-23 meeting.
“1. The following nominees were elected to the Company’s Board of Directors to hold office until the Company’s next Annual Meeting of Shareholders and received the number of votes set forth opposite their names: Names Votes For Votes Against Abstentions Broker Non-Votes Percent of Votes Cast For Douglas M. Baker, Jr. 1,831,441,722 33,955,060 4,441,078 303,475,463 98.17% Mary Ellen Coe 1,831,352,905 33,590,197 4,894,758 303,475,463 98.19% Pamela J. Craig 1,825,716,789 39,919,623 4,201,448 303,475,463 97.86% Robert M. Davis 1,701,209,534 157,428,174 11,200,152 303,475,463 91.52% Thomas H. Glocer 1,727,334,643 137,793,210 4,710,007 303,475,463 92.61% Risa J. Lavizzo-Mourey, M.D. 1,817,190,279 48,426,594 4,220,987 303,475,463 97.40% Stephen L. Mayo, Ph.D. 1,853,609,739 11,176,418 5,051,703 303,475,463 99.40% Paul B. Rothman, M.D. 1,852,736,770 12,058,989 5,042,101 303,475,463 99.35% Patricia F. Russo 1,606,388,270 258,957,288 4,492,302 303,475,463 86.11% Christine E. Seidman, M.D. 1,852,721”
Merck & Co., Inc. reported Full-Year 2022 results: revenue $59.3 Billion, EPS $5.71; $7.48. Guidance initiated.
“Full-Year 2022 Worldwide Sales Were $59.3 Billion, an Increase of 22% From Full Year 2021; Growth Excluding LAGEVRIO Was 12%; Growth Excluding LAGEVRIO and the Impact of Foreign Exchange Was 15% o KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% o GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% - Full-Year 2022 GAAP EPS From Continuing Operations Was $5.71; Full-Year 2022 Non-GAAP EPS Was $7.48”
Merck & Co., Inc. reported Fourth-Quarter 2022 results: revenue $13.8 Billion, EPS $1.18; $1.62. Guidance initiated.
“Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-Quarter 2022 Non-GAAP EPS Was $1.62”
Merck & Co., Inc. updated its the third quarter of 2022 guidance (raised).
“Incorporated by reference is a press release issued by Merck & Co., Inc. (“Merck”) on October 27, 2022, regarding earnings for the third quarter of 2022”
Robert M. Davis was elected as Chairman of the Board at Merck & Co., Inc..
“the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.”
Kenneth C. Frazier departed as Executive Chairman at Merck & Co., Inc..
“Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022.”
Leslie A. Brun resigned as Board of Directors at Merck & Co., Inc..
“announcing the resignation of Leslie A. Brun from the Company’s Board of Directors effective August 19, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.